Registered Rwanda · Rwanda FDA

TORAS-DENK 5

Toresemide

Rwanda FDA-HMP-MA-2316 TABLETS 5 mg

What it does

Toresemide is a medication often used to help remove excess fluid from the body.

Commonly used for: swelling due to heart failure, edema (fluid retention), high blood pressure (hypertension)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
Rwanda FDA-HMP-MA-2316
Registration date
19/06/2025
Expiry date
18/06/2030
Status
Registered
Active ingredient
Toresemide
Dosage form
TABLETS
Strength
5 mg
Pack size
30 Tablets
Therapeutic class
-
Manufacturer / MAH
Denk Pharma
Applicant / LTR
DENK PHARMA GMBH & CO. KG
Country of origin
GERMANY
Manufacturer location
Neherstraße 9, 81675 München, Germany

Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:02 · updated 2026-09-21 02:30:19

Disclaimer: This information is sourced from Rwanda Food and Drugs Authority (Rwanda). Always consult a qualified healthcare professional before using any medication.

About this medicine

Toresemide is a medication often used to help remove excess fluid from the body.

What it treats

  • swelling due to heart failure
  • edema (fluid retention)
  • high blood pressure (hypertension)

How it works

It works by helping the kidneys get rid of extra water and salt, which can reduce swelling and lower blood pressure.

Who it's for

This medication is typically prescribed for adults who have certain conditions related to heart and blood pressure.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: toresemide

Toresemide is a loop diuretic commonly used in the management of conditions associated with fluid overload, such as heart failure and edema. It works by inhibiting the sodium-potassium-chloride co-transporter in the thick ascending limb of the loop of Henle in the nephron, leading to increased excretion of sodium, chloride, and water. This results in diuresis and helps to reduce blood volume and blood pressure.

Indications

  • Congestive heart failure
  • Edema associated with renal disease
  • Edema associated with liver cirrhosis
  • Hypertension

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Toresemide acts primarily on the Na+-K+-2Cl- co-transporter in the thick ascending limb of the loop of Henle, inhibiting the reabsorption of sodium and chloride ions. This inhibition leads to an increase in the osmotic load in the nephron, resulting in increased urinary excretion of sodium, chloride, and water. Additionally, toresemide may exert some effects on renal blood flow and glomerular filtration rate.

Pharmacodynamics

The pharmacodynamic effects of toresemide include its ability to rapidly reduce extracellular fluid volume and lower blood pressure. The onset of diuresis typically occurs within 30 minutes to 1 hour after intravenous administration and within 1 to 2 hours after oral administration, with effects lasting several hours. The degree of diuresis is dose-dependent, and the drug is particularly effective in patients with renal impairment.

Pharmacokinetics

Toresemide is well-absorbed after oral administration, with a bioavailability of approximately 80%. It is highly protein-bound (about 99%) and is metabolized in the liver by cytochrome P450 enzymes, primarily CYP2C9. Its elimination half-life ranges from 3 to 5 hours, with the majority of the drug excreted in the urine, both as unchanged drug and metabolites. Renal function significantly influences the pharmacokinetics of toresemide, necessitating dose adjustments in patients with renal impairment.

Contra-indications

  • Hypersensitivity to toresemide or any of its components
  • Anuria
  • Severe electrolyte depletion

Adverse effects

  • Hypokalemia
  • Dehydration
  • Hypomagnesemia
  • Hypocalcemia
  • Dizziness
  • Tinnitus
  • Ototoxicity
  • Rash
  • Gastrointestinal disturbances

Interactions

  • Other diuretics may increase the risk of electrolyte imbalance
  • Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the diuretic effect
  • Antihypertensive agents may have additive effects leading to hypotension
  • Lithium clearance may be reduced, increasing the risk of lithium toxicity

Precautions

  • Use with caution in patients with renal impairment
  • Monitor electrolytes regularly, especially potassium levels
  • Caution in patients with diabetes mellitus or gout
  • Assess volume status before initiation and during therapy

Pregnancy

Toresemide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is classified as category C.

Breast-feeding

It is not known whether toresemide is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

  • Tablets
  • Injection

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.